Patent intelligence · US
US 11702461
T-cell modulatory multimeric polypeptides comprising reduced-affinity immunomodulatory polypeptides
T-cell modulatory multimeric polypeptides comprising reduced-affinity immunomodulatory polypeptides
Patent details — US 11702461
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 18, 2023
- Expiration
- Jul 13, 2043
- Applicant
- Cue Biopharma, Inc.
- Claims
- 18
- CPC classes
- A61K, A61K2039/605, A61K2039/6056, A61K2039/64
Quick answer
US 11702461 (T-cell modulatory multimeric polypeptides comprising reduced-affinity immunomodulatory polypeptides) is held by Cue Biopharma, Inc.. Status: granted. Granted Jul 18, 2023. Expires Jul 13, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Cue Biopharma, Inc.
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61K, A61K2039/605, A61K2039/6056, A61K2039/64, A61K39/12, A61K39/295
More from Cue Biopharma, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12421287
T-cell modulatory multimeric polypeptides and methods of use thereof
granted -
US 12257311
Multimeric T-cell modulatory polypeptides and methods of use thereof
granted -
US 12180258
T-cell modulatory multimeric polypeptides and methods of use thereof
granted -
US 12152061
T-cell modulatory multimeric polypeptides and methods of use thereof
granted -
US 12145973
T-cell modulatory multimeric polypeptides and methods of use thereof
granted -
US 12029782
MHC class II T-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (T1D) and methods of use thereof
granted -
US 12006348
T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof
granted -
US 11993641
Methods for modulating an immune response
granted
Frequently asked questions
What is US patent 11702461?
US 11702461 (T-cell modulatory multimeric polypeptides comprising reduced-affinity immunomodulatory polypeptides) is held by Cue Biopharma, Inc.. Status: granted. Granted Jul 18, 2023. Expires Jul 13, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11702461?
Cue Biopharma, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 30 pharmaceutical patents for this assignee.
When does US 11702461 expire?
Our index shows an expiration date of Jul 13, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.